The recent paradigm shift in the treatment of glaucoma moving toward earlier intervention, better managing patient compliance and a refocus on addressing the actual pathology continues to move forward with the approval of Durysta, a 10 µg bimatoprost implant for intracameral administration.
With this approval, Durysta (Allergan) becomes the first intracameral, biodegradable sustained-release implant indicated to reduce IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
The FDA approval is based on results from the two 20-month (including 8-month extended
Uncategorized